MARKETS
Earnings

Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate

Aug 11, 2026 · 07:45 AM ET· updated 2h ago

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the

Share
Why It Matters

Neurogene lost more money per share than experts predicted, and its losses got bigger compared to last year. When a company's losses grow faster than expected, it's a sign to watch whether their spending is under control.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.